谷歌掀起人事巨震！Demis Hassabis放权，all in AI制药
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - Demis Hassabis has stepped down as Google DeepMind CEO to become board director and chief scientist, shifting his focus to AI-for-Science and a more active CEO role at AI drug-discovery firm Isomorphic Labs. It signals DeepMind reorienting from single-problem scientific research toward Gemini-driven commercialization and agents, while its founding figures double down on AI-driven drug discovery.
- Broader DeepMind churn: AlphaFold lead John Jumper departed for Anthropic after ~9 years, the AlphaFold team was reportedly disbanded, and the AI4S group is pivoting from protein folding to a full Gemini-powered research system; Jeff Dean is leaving after 27 years to found DiscoveryLoop, an AI-for-science/engineering automation startup that may include drug R&D.
- Isomorphic Labs (spun out of DeepMind in late 2021) aims to build a general-purpose drug design engine reusable across targets and disease areas, rather than per-target pipelines.
- Technical lineage: AlphaFold3 (May 2024, with DeepMind) predicts structures and interactions of all life molecules; IsoDDE (Feb) is claimed to beat physics-based methods on small-molecule binding affinity and more than double AlphaFold3's protein–ligand structure prediction accuracy.
- Commercial footing: $600M raise (Apr 2025, Thrive Capital leading, GV and Alphabet participating) and >$3B in research deals with Novartis and Eli Lilly; clinical entry is described as imminent but has slipped past the previously targeted end-2025, with no disclosed timing, target, or indication.
Sources (1)
谷歌掀起人事巨震！Demis Hassabis放权，all in AI制药
TL;DR - Demis Hassabis has stepped down as Google DeepMind CEO to become board director and chief scientist, shifting his focus to AI-for-Science and a more active CEO role at AI drug-discovery firm Isomorphic Labs. It signals DeepMind reorienting from single-problem scientific research toward Gemini-driven commercialization and agents, while its founding figures double down on AI-driven drug discovery.
- Broader DeepMind churn: AlphaFold lead John Jumper departed for Anthropic after ~9 years, the AlphaFold team was reportedly disbanded, and the AI4S group is pivoting from protein folding to a full Gemini-powered research system; Jeff Dean is leaving after 27 years to found DiscoveryLoop, an AI-for-science/engineering automation startup that may include drug R&D.
- Isomorphic Labs (spun out of DeepMind in late 2021) aims to build a general-purpose drug design engine reusable across targets and disease areas, rather than per-target pipelines.
- Technical lineage: AlphaFold3 (May 2024, with DeepMind) predicts structures and interactions of all life molecules; IsoDDE (Feb) is claimed to beat physics-based methods on small-molecule binding affinity and more than double AlphaFold3's protein–ligand structure prediction accuracy.
- Commercial footing: $600M raise (Apr 2025, Thrive Capital leading, GV and Alphabet participating) and >$3B in research deals with Novartis and Eli Lilly; clinical entry is described as imminent but has slipped past the previously targeted end-2025, with no disclosed timing, target, or indication.